U.S. In Vitro Fertilization Market

The U.S. In Vitro Fertilization Market is valued at USD 152.2 Million in 2023 and is projected to reach a value of USD 326.1 Million by 2032 at a CAGR (Compound Annual Growth Rate) of 8.8% between 2024 and 2032.

Key highlights of U.S. In Vitro Fertilization Market

• In 2023, the Equipment segment dominated the U.S. In Vitro Fertilization market with revenue share of 59.5%
• The Fresh Non-Donor IVF Cycles segment asserted its dominance and accounting for 49.9% in terms of revenue in 2023
• The Conventional IVF segment accounted for the largest revenue share of 48.6% in 2023
• The Fertility Clinics segment led the U.S. In Vitro Fertilization market with revenue share of 56.2% in 2023
• Continuous advancement in the U.S. In Vitro Fertilization research is propelling the market growth. For example, Thermo Fisher Scientific’s new next-generation sequencing-based options to support preimplantation genetic testing-aneuploidy (PGT-A) are used commonly to inform U.S. In Vitro Fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research.

U.S. In Vitro Fertilization Market: Overview

The U.S. In Vitro Fertilization market, valued at USD 152.2 Million in 2023 to USD 326.1 Million in 2032, is anticipated to grow at a CAGR of 8.8% from 2024 to 2032. The U.S. In Vitro Fertilization (IVF) market is flourishing a dynamic shift in evolving sector within reproductive medicine. Technological advancement in association with strict regulatory standards and evolving patient demographics, defines the landscape of assisted reproductive technologies (ART) and fertility treatments in the U.S. As need for IVF services continues to increase, the market remains at the forefront of innovation, propelling advancements in healthcare and offering renewed possibilities for those urging to build their families. Moreover, IVF has emerged as a highly effective treatment option which provides comprehensive array of products, services, and technologies tailored to support patients in their journey towards conception and childbirth.

Product Overview

In 2023, Equipment segment generated a significant revenue of 59.5%. The Product segment is divided into Equipment and Accessories. The U.S. In Vitro Fertilization (IVF) market encompasses a comprehensive array of products and equipment vital for assisted reproductive techniques. Equipment such as sperm analyzer systems, imaging systems, and micromanipulator systems enable precise manipulation and assessment of gametes and embryos. Gas analyzers, cryosystems, and incubators provide optimal conditions for embryo culture and preservation, crucial for successful IVF procedures. IVF cycles are categorized based on whether fresh or frozen embryos are used and whether donor gametes are involved. Types of cycles include fresh non-donor, frozen non-donor, fresh donor, and frozen donor IVF cycles, each presenting unique challenges and considerations for treatment.

Type Overview

The Conventional IVF segment held a significant revenue share of 48.6% in 2023. The Type segment covers Conventional IVF, IVF with ICSI, IVF with Donor Eggs, and Others. Conventional U.S. In Vitro Fertilization (IVF) is a widely utilized assisted reproductive technology that has helped millions of individuals and couples overcome infertility and achieve pregnancy. In conventional IVF, the process begins with the stimulation of the ovaries to produce multiple mature eggs. This is typically achieved through the administration of hormone medications over a period of around 10-14 days. During this time, the response to medication is monitored closely through blood tests and ultrasound examinations to ensure optimal egg development. Once the eggs have reached the appropriate stage of maturity, they are retrieved from the ovaries using a minimally invasive procedure known as transvaginal ultrasound-guided oocyte retrieval. This procedure involves inserting a needle through the vaginal wall and into the ovaries to aspirate the follicular fluid containing the eggs.

End Users Overview

The Fertility Clinics segment accounted for the largest revenue share of 56.2% in 2023. The End Users segment covers Fertility Clinics, Hospitals & Surgical Centers, Cryobanks, and Research Institutes. Fertility clinics are specialist medical facilities that provide individuals and couples facing infertility with comprehensive therapeutic, diagnostic, and supportive care. Performing comprehensive diagnostic evaluations with the goal of identifying the underlying causes of infertility is one of the main functions of fertility clinics. Numerous tests and assessments, including as hormone assessments, semen analysis, ovarian reserve assessments, and imaging techniques like ultrasound or hysterosalpingography, could be a part of this process. Fertility clinics are able to properly determine the underlying reasons of infertility and provide customized treatment plans that are suited to each patient's unique requirements by performing thorough diagnostic evaluations.

Key Trends

• With the continuous evolution of genetic testing technologies, such as preimplantation genetic testing (PGT), IVF clinics can now screen embryos for chromosomal abnormalities and genetic disorders before transfer. This advancement significantly enhances the success rates of IVF treatments.
• The integration of predictive analytics and Artificial Intelligence holds greater potential for revolutionizing IVF practices. By analyzing vast datasets of patient demographics, clinical variables, and treatment parameters, AI algorithms can identify patterns and predictive factors associated with IVF success.
• Telemedicine enables remote consultations, monitoring of treatment progress, and access to support services, offering patients greater convenience, accessibility, and flexibility during fertility treatments.

Premium Insights

As healthcare payers and governments implement initiatives to improve accessibility to reproductive treatments while protecting patient well-being. With this regards, regulatory changes and reimbursement policies play a crucial role in altering the landscape of the U.S. In Vitro Fertilization (IVF) market. For example, the American Society for Reproductive Medicine (ASRM) establish the standards of practice, policies, and moral precepts that regulate IVF centers and medical professionals. The rules implemented by ASRM cover a wide range of topics related to U.S. In Vitro Fertilization (IVF) treatments, such as patient eligibility requirements, informed consent processes, laboratory practices, and ethical issues. IVF facilities can develop patient trust and confidence by following ASRM criteria, which guarantee adherence to strict quality standards.

‹›

Report Coverage & Deliverables

PDF report & online dashboard will help you understand:

• Real-Time Data Updates:
• Competitor Benchmarking
• Market Trends Heatmap
• Custom Research Queries
• Market Sentiment Analysis
• Demographic and Geographic Insights

Book Demo

Get Access Now

Track market trends LIVE & outsmart rivals with our Premium Data Intel Tool: Vantage Point

Market Dynamics

Personalized Medicine and Precision IVF represents a transformative shift in the field of reproductive medicine

There is potential for improving research and development in reproductive medicine through the use of precision IVF procedures and personalized medicine. IVF facilities can generate real-world data, clinical insights, and outcome metrics that can be used to build evidence-based guidelines, best practices, and treatment protocols that further optimize reproductive care and promote ongoing progress in treatment outcomes. Furthermore, future developments in AI algorithms, predictive analytics, and genomic technology will foster innovation and increase the potential for individualized reproductive care.

Expanding Insurance Coverage for Fertility Treatments Drivers the Market

Increase in insurance coverage for fertility treatments, especially U.S. In Vitro Fertilization (IVF) is a major reason for the expansion of the market. Infertility is becoming more widely acknowledged in society as a medical issue that requires complete healthcare coverage, as evidenced by this trend. Fertility treatments were formerly excluded from normal health insurance plans; nevertheless, the availability of insurance coverage for these procedures marks a significant change in healthcare policy and reimbursement methods. Increased patient access to formerly financially unaffordable treatment options results from more insurance plans acknowledging the medical necessity of IVF operations and providing coverage for fertility benefits.

Competitive Landscape

The competitive landscape of the U.S. In Vitro Fertilization (IVF) market has seen notable developments, driven by the introduction of AI-based solutions and technological enhancement help in advancing treatment success rates and patient outcomes. In May 2023, AIVF and Genea Biomedx collaborated to launch an integrated system that combines Genea Biomedx's Geri time-lapse incubator with AIVF's EMA AI platform. Similarly, Oma Fertility made waves by emerging from stealth and introducing a groundbreaking network of fertility clinics. Oma Fertility's clinics leverage AI-informed fertility treatments, setting a new standard for IVF success rates in June 2022.

The key players in the U.S. U.S. In Vitro Fertilization market include - The Cooper Companies Inc., Cook Medical Inc, Thermo Fisher Scientific Inc, Illumina Inc, Becton Dickinson and Co, FUJIFILM Irvine Scientific, Hamilton Thorne Ltd, Vitrolife, Merck KGaA, Esco Medical among others.

Recent Market Developments

• In November 2023, Cooper Companies announced it has closed the acquisition of select Cook Medical assets focused primarily on the obstetrics, doppler monitoring, and gynecology surgery markets. The purchase price was $300 million with $200 million paid at closing and the remaining $100 million to be paid in two $50 million annual installments.
• In July 2023, Thermo Fisher Scientific launched two new next-generation sequencing-based options to support preimplantation genetic testing-aneuploidy (PGT-A) used commonly to inform U.S. In Vitro Fertilization (IVF) and intracytoplasmic sperm injection (ICSI) research. The Ion ReproSeq PGT-A Kit* and the Ion AmpliSeq Polyploidy Kit* mark the first research use reproductive health assays available on the Ion Torrent Genexus Integrated Sequencer*, delivering complete workflows from sample to result for aneuploidy analysis.
• In June 2023, FUJIFILM Irvine Scientific, Inc., announced the addition of the Life Whisperer Genetics module to its Life Whisperer software package, enabling non-invasive evaluation of embryo genetic integrity during U.S. In Vitro Fertilization (IVF).

The U.S. U.S. In Vitro Fertilization market can be categorized as Product, Cycle, Type, and End Users.